Underutilization of evidence-based therapies in heart failure: the pharmacist's role

被引:17
|
作者
Rodgers, Jo Ellen
Stough, Wendy Gattis
机构
[1] Univ N Carolina, Sch Pharm, Chapel Hill, NC 27599 USA
[2] Campbell Univ, Sch Pharm, Res Triangle Pk, NC USA
来源
PHARMACOTHERAPY | 2007年 / 27卷 / 04期
关键词
heart failure; evidence-based therapies; pharmacist's role;
D O I
10.1592/phco.27.4part2.18S
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Utilization of evidence-based therapy in the heart failure population includes implementation of heart failure treatment guidelines, interventions to improve prescribing, and inclusion of pharmacists on the multidisciplinary team. Use of treatment guidelines eases the challenge of selecting the appropriate drug and dosage; quality interventions by pharmacists can ensure optimal prescribing of therapy; and provision of care by a multidisciplinary team can improve outcomes in patients with heart failure. Evidence-based therapy, however, remains underutilized in the heart failure population. Barriers to utilization include misperceptions that various heart failure subpopulations do not need certain medical therapies, a fear of polypharmacy, inappropriate assumptions about adverse effects and contraindications, and cost. In fact, optimal prescribing of evidence-based therapy can actually reduce costs. Clearly documented processes and systems are needed to ensure that evidence-based therapy and education are available to every patient.
引用
收藏
页码:18S / 28S
页数:11
相关论文
共 50 条
  • [1] Factors influencing underutilization of evidence-based therapies in women
    Bugiardini, Raffaele
    Yan, Andrew T.
    Yan, Raymond T.
    Fitchett, David
    Langer, Anatoly
    Manfrini, Olivia
    Goodman, Shaun G.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 (11) : 1337 - 1344
  • [2] Improving implementation of evidence-based therapies for heart failure
    DeVore, Adam D.
    Bosworth, Hayden B.
    Granger, Bradi B.
    [J]. CLINICAL CARDIOLOGY, 2022, 45 : S52 - S59
  • [3] Improve the use of evidence-based heart failure therapies in China
    Hu, Dayi
    [J]. JOURNAL OF CARDIAC FAILURE, 2006, 12 (08) : S157 - S157
  • [4] Utilization of evidence-based therapies for heart failure in the institutionalized elderly
    Shibata, MC
    Soneff, CM
    Tsuyuki, RT
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2005, 7 (07) : 1122 - 1125
  • [5] Significant underutilization of angiotensin receptor neprolysin inhibitor (ARNI) and other evidence-based heart failure (HF) therapies in an outpatient clinic setting
    Singh, N.
    Premji, S.
    Ramakrishnan, D.
    [J]. EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 416 - 417
  • [6] Adherence to Evidence-Based Therapies in Heart Failure Deepening the Implementation Divide
    Bhatt, Ankeet S.
    [J]. JACC-HEART FAILURE, 2021, 9 (12) : 887 - 889
  • [7] Reasons for Lack of Improvement in Treatment With Evidence-Based Therapies in Heart Failure
    Bozkurt, Biykem
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (19) : 2384 - 2387
  • [8] \ The pharmacist's role in managing heart failure
    Tsuyuki, Ross T.
    Arnold, J. Malcolm O.
    [J]. CANADIAN PHARMACISTS JOURNAL, 2006, 139 (03) : 33 - 33
  • [9] Need for Increased Awareness and Evidence-Based Therapies for Patients Hospitalized for Heart Failure
    Butler, Javed
    Fonarow, Gregg C.
    Gheorghiade, Mihai
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (19): : 2035 - 2036
  • [10] Potential impact of optimal implementation of evidence-based heart failure therapies on mortality
    Fonarow, Gregg C.
    Yancy, Clyde W.
    Hernandez, Adrian F.
    Peterson, Eric D.
    Spertus, John A.
    Heidenreich, Paul A.
    [J]. AMERICAN HEART JOURNAL, 2011, 161 (06) : 1024 - U244